Drug resistance in partial epilepsy: epidemiology, mechanisms, pharmacogenetics and therapeutical aspects;La pharmacorésistance des épilepsies partielles : épidémiologie, mécanismes, pharmacogénétique, perspectives thérapeutiques

Neurochirurgie

Volumn 54, Issue 3, 2008, Pages 259-264

  Mann, M W ^a   Pons, G ^b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b Institut Cochin   (France)

Author keywords

Drug resistance; Epilepsy; Multidrug transporters

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE;

ARTICLE; BEHAVIOR CHANGE; COGNITION; ELECTROENCEPHALOGRAM; EPIDEMIOLOGICAL DATA; FEBRILE CONVULSION; FOCAL EPILEPSY; GENE EXPRESSION; GENE MUTATION; HUMAN; MULTIDRUG RESISTANCE; NEUROBIOLOGY; PHARMACEUTICAL ENGINEERING; PHARMACOGENETICS; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SEIZURE;

ANTICONVULSANTS; DRUG RESISTANCE; EPILEPSY; HUMANS; P-GLYCOPROTEINS; PHARMACOGENETICS; RECEPTORS, DRUG;

EID: 43449126476     PISSN: 00283770     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuchi.2008.02.018     Document Type: Article

References (68)

1. Annegers J.F., Hauser W.A., et al. Remission of seizures and relapse in patients with epilepsy. Epilepsia 20 6 (1979) 729-737
2. Arroyo S., Brodie M.J., et al. Is refractory epilepsy preventable?. Epilepsia 43 4 (2002) 437-444
3. Basile V.S., Masellis M., et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 21 1 (1999) 17-27
4. Beck H. Plasticity of antiepileptic drug targets. Epilepsia 48 Suppl. 1 (2007) 14-18
5. Berg A.T., and Kelly M.M. Defining intractability: comparisons among published definitions. Epilepsia 47 2 (2006) 431-436
6. Berg A.T., Langfitt J., et al. How long does it take for partial epilepsy to become intractable?. Neurology 60 2 (2003) 186-190
7. Berg A.T., and Shinnar S. Complex febrile seizures. Epilepsia 37 2 (1996) 126-133
8. Berg A.T., Shinnar S., et al. Early development of intractable epilepsy in children: a prospective study. Neurology 56 11 (2001) 1445-1452
9. Berg A.T., Vickrey B.G., et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann. Neurol. 60 1 (2006) 73-79
10. Borst P., Evers R., et al. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 16 (2000) 1295-1302
11. Briellmann R.S., Torn-Broers Y., et al. APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy. Neurology 55 3 (2000) 435-437
12. Brinkmann U., Roots I., et al. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today 6 16 (2001) 835-839
13. Brooks-Kayal A.R., Shumate M.D., et al. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat. Med. 4 10 (1998) 1166-1172
14. Callaghan B.C., Anand K., et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol. 62 4 (2007) 382-389
15. Cardon L.R., and Bell J.I. Association study designs for complex diseases. Nat. Rev. Genet. 2 2 (2001) 91-99
16. Chang B.S., and Lowenstein D.H. Epilepsy. N. Engl. J. Med. 349 13 (2003) 1257-1266
17. Cockerell O.C., Johnson A.L., et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 346 8968 (1995) 140-144
18. Cockerell O.C., Johnson A.L., et al. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 38 1 (1997) 31-46
19. Dean M., Rzhetsky A., et al. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11 7 (2001) 1156-1166
20. Devinsky O. Patients with refractory seizures. N. Engl. J. Med. 340 20 (1999) 1565-1570
21. Dombrowski S.M., Desai S.Y., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 12 (2001) 1501-1506
22. Edwards R.H. Drug delivery via the blood-brain barrier. Nat. Neurosci. 4 3 (2001) 221-222
23. Elwes R.D., Johnson A.L., et al. The prognosis for seizure control in newly diagnosed epilepsy. N. Engl. J. Med. 311 15 (1984) 944-947
24. Gambardella A., Manna I., et al. GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology 60 4 (2003) 560-563
25. Gourfinkel-An I., Baulac S., et al. Monogenic idiopathic epilepsies. Lancet Neurol. 3 4 (2004) 209-218
26. Hauser W.A., Rich S.S., et al. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 40 8 (1990) 1163-1170
27. Heils A., Haug K., et al. Interleukin-1beta gene polymorphism and susceptibility to temporal lobe epilepsy with hippocampal sclerosis. Ann. Neurol. 48 6 (2000) 948-950
28. Hermann B.P., Seidenberg M., et al. Cognitive prognosis in chronic temporal lobe epilepsy. Ann. Neurol. 60 1 (2006) 80-87
29. Hitiris N., Mohanraj R., et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 75 2-3 (2007) 192-196
30. Hoffmeyer S., Burk O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97 7 (2000) 3473-3478
31. Hung C.C., Tai J.J., et al. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6 4 (2005) 411-417
32. Kanemoto K., Kawasaki J., et al. Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Ann. Neurol. 47 5 (2000) 571-574
33. Kim Y.O., Kim M.K., et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 15 1 (2006) 67-72
34. Ko T.S., and Holmes G.L. EEG and clinical predictors of medically intractable childhood epilepsy. Clin. Neurophysiol. 110 7 (1999) 1245-1251
35. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342 5 (2000) 314-319
36. Kwan P., and Brodie M.J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46 2 (2005) 224-235
37. Leschziner G., Jorgensen A.L., et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol. 5 8 (2006) 668-676
38. Löscher W., and Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301 1 (2002) 7-14
39. Mann M.W., and Pons G. Various pharmacogenetic aspects of antiepileptic drug therapy: a review. CNS Drugs 21 2 (2007) 143-164
40. Mattson, R.H., Cramer, J.A. et al., 1996. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Neurology 47 (1), 68-76.
41. Moulard B., Crespel A., et al. Recent insights about genetics of human idiopathic epilepsies and febrile seizures. Rev. Neurol. (Paris) 156 10 (2000) 819-828
42. Ott J. Association of genetic loci: Replication or not, that is the question. Neurology 63 6 (2004) 955-958
43. Owen A., Pirmohamed M., et al. Carbamazepine is not a substrate for P-glycoprotein. Br. J. Clin. Pharmacol. 51 4 (2001) 345-349
44. Potschka H., Baltes S., et al. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res. 58 2-3 (2004) 85-91
45. Remy S., Gabriel S., et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol. 53 4 (2003) 469-479
46. Salzmann A., Moulard B., et al. GABA receptor 1 polymorphism (G1465A) and temporal lobe epilepsy. Epilepsia 46 6 (2005) 931-933
47. Sander T., Berlin W., et al. Genetic variation of the human mu-opioid receptor and susceptibility to idiopathic absence epilepsy. Epilepsy Res. 39 1 (2000) 57-61
48. Scheffer G.L., Wijngaard P.L., et al. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1 6 (1995) 578-582
49. Semah F., Picot M.C., et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence?. Neurology 51 5 (1998) 1256-1262
50. Seo T., Ishitsu T., et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7 4 (2006) 551-561
51. Shafer S.Q., Hauser W.A., et al. EEG and other early predictors of epilepsy remission: a community study. Epilepsia 29 5 (1988) 590-600
52. Siddiqui A., Kerb R., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348 15 (2003) 1442-1448
53. Sillanpaa M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia 34 5 (1993) 930-936
54. Sills G.J., Kwan P., et al. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav. 3 5 (2002) 427-432
55. Sills G.J., Mohanraj R., et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46 5 (2005) 643-647
56. Sisodiya S.M., Lin W.R., et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125 Pt 1 (2002) 22-31
57. Sisodiya S.M., Lin W.R., et al. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 357 9249 (2001) 42-43
58. Sperling M.R. The consequences of uncontrolled epilepsy. CNS Spectr. 9 2 (2004) 98-101 106-109
59. Steen V.M., Lovlie R., et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry 2 2 (1997) 139-145
60. Stogmann E., Zimprich A., et al. A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy. Ann. Neurol. 51 2 (2002) 260-263
61. Tan N.C., Heron S.E., et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63 6 (2004) 1090-1092
62. Tilgen N., Rebstock J., et al. Prodynorphin gene promoter polymorphism and temporal lobe epilepsy. Ann. Neurol. 53 2 (2003) 280-281 (author reply 281-2)
63. Tsai F.J., Hsieh Y.Y., et al. Polymorphisms for interleukin 1 beta exon 5 and interleukin 1 receptor antagonist in Taiwanese children with febrile convulsions. Arch. Pediatr. Adolesc. Med. 156 6 (2002) 545-548
64. Vadlamudi L., Scheffer I.E., et al. Genetics of temporal lobe epilepsy. J. Neurol. Neurosurg. Psychiatry 74 10 (2003) 1359-1361
65. Vreugdenhil M., van Veelen C.W., et al. Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res. 32 1-2 (1998) 309-320
66. Vreugdenhil M., and Wadman W.J. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia 40 11 (1999) 1512-1522
67. Wijnholds J. Drug resistance caused by multidrug resistance-associated proteins. Novartis Found. Symp. 243 (2002) 69-79 (discussion 80-2, 180-5)
68. Zimprich F., Sunder-Plassmann R., et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63 6 (2004) 1087-1089